Here's the Incredible Promise of Medicine That Targets Our DNA
Around the world, people suffer from a genetic condition called hemophilia. Even with expensive and time-consuming treatments, simple injuries for these patients hold the threat of turning into serious complications and even life-threatening events. But now, one biotech company has stumbled upon what very early trials suggest could be a "cure" -- something that, with a single intravenous drip, essentially corrects the genetic mutation that causes the disorder. This week, Bloomberg's Doni Bloomfield visits the scientists behind this treatment and a patient who has actually tried it. If it works, researchers may have pushed the door open to a whole new world of treatments that tackle these diseases at their source: our DNA.
Want to hear more? Subscribe on iTunes and Pocket Casts for new episodes every week. Decrypted is a podcast that uncovers the hidden projects, quiet rivalries and uncomfortable truths in the global technology industry.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.